312 related articles for article (PubMed ID: 21984449)
1. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.
Dahlqvist Leinhard O; Dahlström N; Kihlberg J; Sandström P; Brismar TB; Smedby O; Lundberg P
Eur Radiol; 2012 Mar; 22(3):642-53. PubMed ID: 21984449
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
3. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
4. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
5. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
7. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
8. Chimeric mouse model for MRI contrast agent evaluation.
Mir FF; Tomaszewski RP; Shuboni-Mulligan DD; Mallett CL; Hix JML; Ether ND; Shapiro EM
Magn Reson Med; 2019 Jul; 82(1):387-394. PubMed ID: 30874333
[TBL] [Abstract][Full Text] [Related]
9. Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents--comparison of Gd-EOB-DTPA and Gd-BOPTA.
Ringe KI; Boll DT; Husarik DB; Bashir MR; Gupta RT; Merkle EM
BMC Med Imaging; 2013 Mar; 13():10. PubMed ID: 23506523
[TBL] [Abstract][Full Text] [Related]
10. Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA.
Norén B; Forsgren MF; Dahlqvist Leinhard O; Dahlström N; Kihlberg J; Romu T; Kechagias S; Almer S; Smedby Ö; Lundberg P
Eur Radiol; 2013 Jan; 23(1):174-81. PubMed ID: 22836161
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Quantitative Lung Perfusion Imaging Using the Dual-Bolus Approach: Comparison of 3 Contrast Agents and Recommendation of Feasible Doses.
Veldhoen S; Oechsner M; Fischer A; Weng AM; Kunz AS; Bley TA; Köstler H; Ritter CO
Invest Radiol; 2016 Mar; 51(3):186-93. PubMed ID: 26606550
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents.
Ciolina M; Di Martino M; Bruno O; Pommier R; Vilgrain V; Ronot M
Eur Radiol; 2018 Jul; 28(7):3020-3031. PubMed ID: 29374320
[TBL] [Abstract][Full Text] [Related]
14. How transfer rates generate Gd-BOPTA concentrations in rat liver compartments: implications for clinical liver imaging with hepatobiliary contrast agents.
Pastor CM
Contrast Media Mol Imaging; 2016 Jul; 11(4):291-8. PubMed ID: 27060676
[TBL] [Abstract][Full Text] [Related]
15. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.
Verloh N; Haimerl M; Zeman F; Schlabeck M; Barreiros A; Loss M; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
Eur Radiol; 2014 May; 24(5):1013-9. PubMed ID: 24531844
[TBL] [Abstract][Full Text] [Related]
16. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
17. [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].
Stroszczynski C; Gaffke G; Gnauck M; Streitparth F; Wieners G; Lopez-Häninnen E
Radiologe; 2004 Dec; 44(12):1185-91. PubMed ID: 15549226
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA.
Planchamp C; Pastor CM; Balant L; Becker CD; Terrier F; Gex-Fabry M
Invest Radiol; 2005 Nov; 40(11):705-14. PubMed ID: 16230903
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
[TBL] [Abstract][Full Text] [Related]
20. MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score.
Haimerl M; Verloh N; Fellner C; Zeman F; Teufel A; Fichtner-Feigl S; Schreyer AG; Stroszczynski C; Wiggermann P
Sci Rep; 2014 Jul; 4():5621. PubMed ID: 25001391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]